| 7.33 0.11 (1.52%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.69 | 1-year : | 10.15 |
| Resists | First : | 7.44 | Second : | 8.69 |
| Pivot price | 6.84 |
|||
| Supports | First : | 5.71 | Second : | 4.65 |
| MAs | MA(5) : | 7.1 |
MA(20) : | 6.43 |
| MA(100) : | 3.71 |
MA(250) : | 2.59 |
|
| MACD | MACD : | 0.6  |
Signal : | 0.7 |
| %K %D | K(14,3) : | 89.9 |
D(3) : | 86.1 |
| RSI | RSI(14): 65.6 |
|||
| 52-week | High : | 16.34 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARMP ] has closed below upper band by 22.1%. Bollinger Bands are 24.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.41 - 7.45 | 7.45 - 7.48 |
| Low: | 7.02 - 7.06 | 7.06 - 7.1 |
| Close: | 7.15 - 7.22 | 7.22 - 7.28 |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Wed, 12 Nov 2025
Armata Pharma (NYSE American: ARMP) commissions LA cGMP plant; 56,000 sq ft with automated fill-finish - Stock Titan
Wed, 12 Nov 2025
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 23 Oct 2025
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 1.104e+007 (%) |
| Held by Institutions | 70.2 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.091e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 130.8 % |
| Return on Equity (ttm) | -25.1 % |
| Qtrly Rev. Growth | 3.72e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.68 |
| Dividend | 0 |
| Forward Dividend | 7030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|